



**Do you have advanced squamous cell lung cancer?
Have you had chemotherapy already?
Talk with your doctor about the Lung-MAP research study.**

Usual Care

If you have the type of lung cancer called squamous cell lung cancer that is advanced – Stage IV that may have spread to other organs – usual care often involves chemotherapy. Even when initial chemotherapy works, lung cancer often returns. You would then be eligible to receive different therapies. These are known as “second-line” or “third-line” treatments.

Purpose of This Study

The Lung-MAP study is a large clinical trial that is testing new treatments for patients who have advanced stage squamous cell lung cancer. There are many different changes to a person’s cancer genes that can cause squamous cells to grow out of control. Researchers have developed new drugs that might “target” these genetic changes better and with fewer side effects. The Lung-MAP study hopes to learn if the drugs that target the genetic changes in the cancer cells will slow or stop the squamous cell lung cancer from growing.

Lung-MAP is focused on advanced squamous cell lung cancer because there are few effective treatments for these patients, particularly those who don’t respond to chemotherapy.

What if my tumor does not have the genetic change?

For some patients, their tumor will not match the genetic changes that are being tested in the trial. However, these patients may be able to join the “non-match” sub-study in Lung-MAP.

This “non-match” sub-study tests drugs that may help the immune system fight the cancer cells. Patients will be randomly assigned to be on one of two groups. Both offer a

drug, nivolumab, which is approved for safety and effectiveness by the U.S. Food and Drug Administration for patients with advanced squamous cell lung cancer. One group of patients will be treated with nivolumab alone; the other will receive nivolumab plus another drug, ipilimumab.

Benefits of Taking Part in This Study

It is not possible to know at this time if the study drugs are better than the usual treatment approach, so this study may or may not help you. However, this study will help researchers learn things that will help people in the future.

Risks of Taking Part in This Study

- We may need to take another biopsy of your tumor, which has some risks. You may have some bleeding, pain, or bruising. You may also develop an infection.
- You may have side effects from the drugs used.
- There may be privacy risks. We have strict rules and procedures in place to protect your identity, but we cannot guarantee that your identity will never become known.

Costs of Taking Part in This Study

Study sponsors pay for the genetic testing of your tumor tissue and the investigational drug.. You and your insurance company will need to pay for other care costs. Check with your insurance company to find out what it will and will not pay for. Patients who enroll in Lung-MAP will not be compensated.

You Can Stop At Any Time

If you change your mind about taking part in this study for any reason, you can stop at any time. We also may ask you to stop the study if we believe it is in your best interest, if new information becomes available, if you do not follow the study rules, or if the study is stopped.